Research programme: antiviral compounds - Access

Drug Profile

Research programme: antiviral compounds - Access

Alternative Names: Antiviral compounds research programme - Access

Latest Information Update: 19 Oct 2005

Price : $50

At a glance

  • Originator Access Pharmaceuticals
  • Class
  • Mechanism of Action HIV replication inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported HIV infections; HTLV-I infections; HTLV-II infections

Most Recent Events

  • 19 Oct 2005 No development reported - Preclinical for HTLV-II infections in USA (unspecified route)
  • 19 Oct 2005 No development reported - Preclinical for HTLV-I infections in USA (unspecified route)
  • 19 Oct 2005 No development reported - Preclinical for HIV infections treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top